Efficacy and tolerability of peginterferon alfa-2a (40kd) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions

被引：0
|
作者：
Zehnter, E. [1 ]
Mauss, S. [18 ]
Kaiser, S. [2 ]
Boeker, K. [3 ]
Lutz, T. [4 ]
Heyne, R. [5 ]
John, C. [6 ]
Moog, G. [7 ]
Schober, A. [8 ]
Pfaff, R. [9 ]
Zipf, A. [10 ]
Racky, S. [11 ]
Lohmeyer, J. [12 ]
Bokemeyer, B. [13 ]
Kallinowski, B. [14 ]
Witthoeft, T. [15 ]
Alshuth, U. [16 ]
Hueppe, D. [17 ]
机构：
[1] Ctr Gastroenterol, Dortmund, Germany
[2] Klinikum Eberhard Karls Univ, Tubingen, Germany
[3] Ctr Gastroenterol, Hannover, Germany
[4] Infektiologikum, Frankfurt, Germany
[5] Ctr Gastroenterol & Liver Ctr, Berlin, Germany
[6] Ctr Gastroenterol, Berlin, Germany
[7] Ctr Gastroenterol, Kassel, Germany
[8] Ctr Gastroenterol, Gottingen, Germany
[9] Ctr Gastroenterol, Giessen, Germany
[10] Ctr Gastroenterol, Mannheim, Germany
[11] Ctr Gastroenterol, Bad Schwalbach, Germany
[12] Univ Giessen, Giessen, Germany
[13] Ctr Gastroenterol, Minden, Germany
[14] Ctr Gastroenterol, Schwetzingen, Germany
[15] Univ Hosp Schleswig Holstein, Div Gastroenterol, Dept Med 1, Lubeck, Germany
[16] Roche Pharma AG, BU Hepatitis HIV CF, Grenzach Wyhlen, Germany
[17] Ctr Gastroenterol, Herne, Germany
[18] Ctr HIV & Hepatogastrenterol, Dusseldorf, Germany
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60844-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
842
引用
收藏
页码：S316 / S316
页数：1
相关论文
共 50 条
  • [21] Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Reau, Nancy
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Fried, Michael W.
    Jensen, Donald M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 1981 - 1988
  • [22] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [23] Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis CHCV genotype 1:: Safety and tolerability.
    Howell, C
    Jeffers, LS
    Cassidy, W
    Reddy, R
    Sheridan, S
    Ho, I
    Khouri, S
    Harb, G
    HEPATOLOGY, 2003, 38 (04) : 319A - 319A
  • [24] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
  • [25] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [26] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [27] EFFICACY AND TOLERABILITY OF PEGINTERFERON ALPHA-2A (40KD) AND RIBAVIRIN IN RELAPSE-PATIENTS UNDER REAL-LIFE CONDITIONS
    Zehnter, Elmar
    Mauss, Stefan
    Boeker, Klaus
    Schober, Andreas
    Moog, Gero
    Lutz, Thomas
    Schuchmann, Marcus
    Heyne, Renate
    Schiffelholz, Willi
    John, Christine
    Hey, Karl-Heinz
    Baumgarten, Axel
    Geyer, Peter R.
    Pape, Stefan
    Lohmeyer, Juergen
    Schmidt, Wolfgang
    Alshuth, Ulrich
    Hueppe, Dietrich
    HEPATOLOGY, 2010, 52 (04) : 799A - 800A
  • [28] Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40KD)/RBV
    Shobokshi, O
    Serebour, FE
    Skakni, L
    Al-Jasser, N
    Tantawi, AO
    Sabah, A
    Dinish, T
    Al-Quaiz, M
    Qahtani, K
    Sandokji, A
    Al-Blowi, A
    Al-Karawi, M
    Al-Kayyal, B
    Al-Momen, S
    Akbar, H
    Ayoola, A
    El-Hazmi, M
    Humaida, A
    El-Hazmi, I
    Eissa, H
    Khawajah, F
    Al-Khalifa, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 172 - 172
  • [29] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
  • [30] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
12345